{"nctId":"NCT02116530","briefTitle":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","startDateStruct":{"date":"2014-08-20","type":"ACTUAL"},"conditions":["Hematopoietic/Lymphoid Cancer","Nausea and Vomiting","Unspecified Adult Solid Tumor, Protocol Specific"],"count":401,"armGroups":[{"label":"Olanzapine + Chemotherapy + Antiemetic treatment","type":"EXPERIMENTAL","interventionNames":["Drug: Olanzapine","Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)","Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)"]},{"label":"Placebo + Chemotherapy + Antiemetic treatment","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)","Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)","Other: Placebo"]}],"interventions":[{"name":"Olanzapine","otherNames":[]},{"name":"Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)","otherNames":[]},{"name":"Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"* Diagnosis of malignant disease\n* No prior chemotherapy and scheduled to receive HEC (either cisplatin-containing regimen or anthracycline + cyclophosphamide \\[AC\\])\n\n  * Cisplatin at a dose of ≥70mg/m\\^2, with or without other chemotherapy agent(s) OR\n  * Anthracycline (60 mg/m\\^2) plus cyclophosphamide(600 mg/m\\^2)\n* Age ≥18 years\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2\n* Required Initial Laboratory Values ≤ 120 days prior to registration\n\n  * Serum Creatinine ≤2.0 mg/dL\n  * Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic oxaloacetic transaminase (SGPT) ≤3 x Upper Limit of Normal (ULN)\n  * Absolute neutrophil count (ANC) ≥1500/mm\\^3\n* No nausea or vomiting ≤ 24 hours prior to registration\n* Negative pregnancy test (serum or urine) done ≤7 days prior to registration, for women of childbearing potential only (per clinician discretion)\n* No severe cognitive compromise\n* No known history of CNS disease (e.g. brain metastases, seizure disorder)\n* No treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone ≤30 days prior to registration or planned during protocol therapy\n* No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy)\n* No concurrent use of amifostine\n* No concurrent abdominal radiotherapy\n* No concurrent use of quinolone antibiotic therapy\n* No chronic alcoholism (as determined by the investigator)\n* No known hypersensitivity to olanzapine\n* No known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months.\n* No history of uncontrolled diabetes mellitus (e.g. on insulin or an oral hypoglycemic agent)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients With no Nausea","description":"No nausea was defined as a response of 0 in the nausea item of Nausea and Vomiting Daily Diary/Questionnaire in the acute (0-24 hours), delayed (25-120 hours) and overall (0-120 hours) periods after chemotherapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null},{"groupId":"OG001","value":"45.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.4","spread":null},{"groupId":"OG001","value":"25.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37.3","spread":null},{"groupId":"OG001","value":"21.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Median Nausea Scores","description":"Nausea scores was measured using a visual-analogue scale ranging from 0 (none) to 10 (as bad as it can be).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Patients With Complete Response","description":"Complete response was defined as no emetic episodes and no use of rescue medication during the acute (0-24 hours), delayed (25-120 hours) and overall (0-120 hours) periods as measured by the Nausea and Vomiting Daily Diary/Questionnaire.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.7","spread":null},{"groupId":"OG001","value":"64.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"66.9","spread":null},{"groupId":"OG001","value":"52.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.6","spread":null},{"groupId":"OG001","value":"40.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Scores of Potential Toxicities Related to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire","description":"Patients were asked to record daily levels of undesired sedation and appetite increase using a visual-analogue scale ranging from 0 (none) to 10 (as bad as it can be).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"1.2"},{"groupId":"OG001","value":"0.5","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.3","spread":"3.2"},{"groupId":"OG001","value":"1.2","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":"2.5"},{"groupId":"OG001","value":"1.4","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"2.3"},{"groupId":"OG001","value":"1.4","spread":"2.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"2.1"},{"groupId":"OG001","value":"1.2","spread":"2.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.8"},{"groupId":"OG001","value":"1.3","spread":"2.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"1.7"},{"groupId":"OG001","value":"0.3","spread":"0.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.6"},{"groupId":"OG001","value":"0.5","spread":"1.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"1.5"},{"groupId":"OG001","value":"0.6","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.8"},{"groupId":"OG001","value":"0.7","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.8"},{"groupId":"OG001","value":"0.7","spread":"1.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"2.0"},{"groupId":"OG001","value":"0.7","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Frequency of Rescue Medication","description":"Patients were asked to record daily number of extra nausea/vomiting pills taken because they developed nausea/vomiting in the following categories: None, One, Two, More than two in Nausea and Vomiting Daily Diary Questionnaire.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"156","spread":null},{"groupId":"OG001","value":"117","spread":null}]},{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"35","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"19","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"158","spread":null},{"groupId":"OG001","value":"124","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"24","spread":null}]},{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"20","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"124","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"24","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"17","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"145","spread":null},{"groupId":"OG001","value":"131","spread":null}]},{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"23","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143","spread":null},{"groupId":"OG001","value":"130","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"16","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":188},"commonTop":["Somnolence","Fatigue","Nausea","Headache","Dizziness"]}}}